Conditions: Compliance Behavior
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 23
Healthy volunteers: no

Brief summary:
Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.

Detailed description:
Patients with NASH to receive the treatment versus placebo for 40 weeks followed by a liver biopsy.

Arms:
arm 1: Normal saline administered orally daily as a placebo arm 2: Beta glucosylceramide administered orally daily

Interventions: intervention 1: Beta Glucosylceramide intervention 2: Placebo
Intervention descriptions: intervention 1: Beta Glucosylceramide intervention 2: normal saline

Protocol document: